Gemcitabine

Introduction Overview

Generic Name

gemcitabine

Brand Name

Gemzar

Dosage Form

Intravenous infusion

Drug Class

Antimetabolites

Pharmacokinetics

Absorption:
Gemcitabine is administered intravenously; therefore, it bypasses gastrointestinal absorption and enters directly into the systemic circulation. This intravenous route ensures 100% bioavailability, allowing precise control of plasma concentrations. Clinical studies have demonstrated that gemcitabine reaches peak plasma levels rapidly at the end of infusion, generally within 30 minutes to 2 hours, depending on the infusion schedule employed in treatment protocols.

Distribution:
Following intravenous administration, gemcitabine exhibits a two-compartment pharmacokinetic profile. It has a large volume of distribution, approximately 40 to 50 L/m2, indicating extensive distribution into body tissues beyond plasma. Gemcitabine is moderately bound to plasma proteins, approximately 20%, which is relatively low and clinically insignificant in altering free drug concentrations. Due to its hydrophilic nature, gemcitabine distributes predominantly into extracellular fluid compartments. Preclinical findings suggest penetration into tumor tissues, but variable infiltration may occur depending on tumor vascularity and interstitial pressure.

Metabolism:
Gemcitabine undergoes rapid deamination primarily in the liver but also in other tissues such as the blood, kidney, and lungs. Cytidine deaminase converts gemcitabine into its inactive metabolite 2',2'-difluorodeoxyuridine (dFdU). This metabolic process is extensive and rapid, contributing to gemcitabine's short plasma half-life. Additionally, intracellular phosphorylation leads to the formation of active triphosphate metabolites which exert cytotoxic effects. Variability in cytidine deaminase activity among patients can influence gemcitabine clearance and toxicity profiles.

Elimination:
The primary route of elimination for gemcitabine is renal excretion of metabolites rather than unchanged drug. Less than 10% of an administered dose is excreted unchanged in urine. The plasma elimination half-life is short, typically around 42 to 94 minutes after infusion, due to rapid metabolism and clearance. Renal impairment can significantly affect clearance of metabolites, necessitating dosage adjustments. Clinical pharmacokinetic studies recommend monitoring and dose modification in patients with compromised renal function. Overall, gemcitabine clearance is dependent on hepatic cytidine deaminase activity and renal excretion efficiency.

Dosage Forms

Available Dosage Forms:
Gemzar is supplied exclusively in formulations suitable for intravenous infusion. The commercially available formulations include sterile lyophilized powder for reconstitution.

- Gemcitabine for injection comes as a powder in single-dose vials, typically in strengths of 200 mg, 1000 mg, and 1500 mg per vial.

Dosages for Adults and Adolescents:
The dosing regimen is highly dependent on indication and treatment protocol. Common dosing strategies include:
- For non-small cell lung cancer: 1000 mg/m2 administered intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
- For pancreatic cancer: 1000 mg/m2 intravenously over 30 minutes weekly for seven weeks followed by a one-week rest, then 1000 mg/m2 on days 1, 8, 15 of a 28-day cycle.
- For ovarian and breast cancer: Variable regimens involving 1000-1250 mg/m2 doses on days 1 and 8 every 21 days.
Dose adjustments are typically based on hematologic toxicity, renal and hepatic function.

Specific Patient Populations:
- Renal impairment: Dose reductions are recommended for patients with moderate to severe renal dysfunction, with careful monitoring of renal function and toxicity.
- Hepatic impairment: While gemcitabine is primarily metabolized by cytidine deaminase in the liver, no standard dose adjustment is necessary, but monitoring for toxicity is advised.
- Elderly patients: No formal dosage adjustment solely based on age, but clinical status and organ function should guide dosing.
- Pediatric patients: Limited data; usage generally restricted to clinical trials or specialist recommendations.

Dosage regimens must always be individualized based on disease type, patient tolerance, hematologic status, and clinical response.

Mechanism Of Action

Gemcitabine is a nucleoside analog of deoxycytidine and functions as an antimetabolite, interfering with DNA synthesis and cell replication. Once inside cells, gemcitabine is phosphorylated by deoxycytidine kinase into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleotides, which are essential for its cytotoxic activity.

The diphosphate metabolite inhibits ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides, thereby depleting the pool of deoxynucleotides necessary for DNA synthesis and repair. This depletion leads to DNA synthesis inhibition and sensitizes cells to gemcitabine’s incorporation.

The triphosphate metabolite is directly incorporated into the nascent DNA strand during replication. Incorporation causes masked chain termination: gemcitabine allows the incorporation of one additional nucleotide before halting DNA elongation, which interferes with DNA repair mechanisms and triggers apoptotic pathways. This unique mechanism increases cytotoxicity and impedes cancer cell proliferation.

Clinically, gemcitabine induces cell cycle arrest predominantly in the S-phase and promotes apoptosis through multiple signaling pathways. Comparative studies show gemcitabine shares mechanistic traits with other nucleoside analogues but exhibits improved uptake, intracellular retention, and a distinctive masked chain termination pattern. These characteristics contribute to its efficacy in various solid tumors, especially pancreatic and non-small cell lung cancers. Ongoing research investigates gemcitabine combinations to enhance synergistic effects and overcome resistance mechanisms.

Pharmacological Actions

Inhibits DNA synthesis by acting as a nucleoside analog antimetabolite.
Inhibits ribonucleotide reductase, leading to depletion of deoxyribonucleotides.
Causes masked chain termination upon incorporation into DNA, halting DNA replication.
Induces S-phase cell cycle arrest and promotes apoptosis in rapidly dividing cancer cells.
Exerts cytotoxic effects preferentially on proliferating malignant cells.
Modulates tumor microenvironment, potentially enhancing immune recognition.
Synergistic cytotoxicity when combined with other chemotherapeutic agents.
Interferes with DNA repair mechanisms, increasing susceptibility to DNA damage.
Exhibits anti-tumor activity in a broad spectrum of solid tumors.
Metabolized intracellularly into active phosphorylated metabolites critical for efficacy.
Demonstrates impaired activity in cells deficient in nucleoside transport or phosphorylation enzymes.
Pharmacodynamic activity closely linked to infusion schedule and plasma concentrations.
Sensitivity influenced by variations in cytidine deaminase activity, affecting metabolism.
Triggers apoptotic pathways involving mitochondrial membrane potential disruption.
Reduces tumor growth by decreasing cancer cell proliferation and viability.

Therapeutic Or Clinical Uses

Treatment of locally advanced and metastatic pancreatic adenocarcinoma.
Management of non-small cell lung cancer, particularly in advanced or metastatic stages.
Therapeutic agent for ovarian cancer, including refractory or recurrent disease.
Used in combination regimens for breast cancer therapy.
Treatment option for bladder cancer in select protocols.
Employed in management of biliary tract cancers as part of combination chemotherapy.
Indicated for use in soft tissue sarcomas and other less common solid tumors in clinical trials.
Used when other cancer treatments have failed or cancer has recurred.
Part of first-line chemotherapeutic regimens for various epithelial tumors.
Off-label use in certain hematologic malignancies under investigational settings.
Adjuvant or neoadjuvant therapy component in multimodality treatment plans.
Palliative treatment to improve symptoms and quality of life in advanced malignancies.
Used in elderly patients with tailored dosage regimens based on tolerance.
Applied in combination with radiation therapy with caution due to increased toxicity.
May be used in clinical trials evaluating novel combination therapies to improve outcomes.

Side Or Adverse Effects

Myelosuppression manifesting as neutropenia, thrombocytopenia, and anemia.
Fever and increased risk of infections due to immunosuppression.
Nausea and vomiting, often manageable with antiemetic therapy.
Flu-like symptoms including fever, chills, fatigue, and malaise.
Elevated liver enzymes indicating hepatotoxicity; monitoring required.
Pulmonary toxicity presenting as pneumonitis, dyspnea, or pulmonary edema.
Skin reactions including rash, erythema, and radiation recall dermatitis.
Renal impairment concerns especially in patients with pre-existing kidney disease.
Allergic reactions ranging from mild hypersensitivity to anaphylaxis.
Mucositis causing painful mouth ulcers and difficulty swallowing.
Peripheral edema and fluid retention leading to weight gain and discomfort.
Central nervous system effects such as headache, confusion, or seizures in rare cases.
Bleeding tendency due to thrombocytopenia and platelet dysfunction.
Abnormal urine discoloration, commonly reddish or pink hue without hematuria.
Fatigue and asthenia impacting patient quality of life during therapy.

Precautions

Monitor complete blood counts regularly due to risk of severe myelosuppression.
Careful assessment and adjustment in patients with impaired renal or hepatic function.
Avoid live vaccines during treatment because of potential for infection.
Educate patients on signs of infection or bleeding and advise immediate reporting.
Use effective contraception during treatment and for designated periods after therapy ends.
Perform pregnancy testing before starting therapy in women of childbearing potential.
Advise against breastfeeding during and for at least one week after treatment completion.
Monitor pulmonary function for early detection of lung toxicity.
Administer drug via intravenous infusion only, avoiding extravasation to prevent tissue injury.
Use caution in patients with prior radiation therapy due to enhanced skin toxicity.
Assess liver function tests regularly and watch for signs of hepatotoxicity.
Implement infection prophylaxis as indicated based on neutropenia severity.
Adjust dosing or delay treatment cycles based on hematologic and non-hematologic toxicities.
Counsel patients on minimizing exposure to infectious contacts during immunosuppression.
Use protective gloves and precautions when handling patient body fluids due to drug excretion.

Warnings

Potential for severe myelosuppression resulting in infections, bleeding, and anemia.
Risk of life-threatening allergic reactions requiring emergency management.
Hepatotoxicity with signs of jaundice, dark urine, and elevated liver enzymes.
Pulmonary toxicity including potentially fatal interstitial pneumonitis and pulmonary edema.
Increased skin reactions and severe dermatitis with concurrent or recent radiotherapy.
Fetal toxicity and teratogenic effects; contraindicated in pregnancy.
Risk of fertility impairment, counsel patients regarding reproductive planning.
Avoid administration with live vaccines due to risk of viral infection from immunocompromise.
Necessity for close monitoring due to rapid and unpredictable toxicity onset.
Delayed or permanent discontinuation of chemotherapy may be required upon severe adverse reactions.
Gemcitabine exposure to caregivers should be minimized due to its cytotoxic nature.
Potential for cumulative toxicity with repeated dosing necessitates ongoing evaluation.
Caution with use in patients with pre-existing cardiac or pulmonary conditions.
Hospital monitoring advised for patients exhibiting severe neurological or systemic side effects.
Risk of extravasation during intravenous infusion causing local tissue damage.

Contraindication

Known hypersensitivity to gemcitabine or any component of the formulation.
Pregnancy due to risk of fetal harm and teratogenicity.
Active, uncontrolled infections until resolution due to increased infection risk.
Severe myelosuppression or baseline low blood counts contraindicating further marrow suppression.
Concomitant administration with live vaccines is contraindicated during and shortly after therapy.
Severe hepatic impairment precluding safe metabolism and elimination of the drug.
Severe renal impairment without possibility of dose adjustment or monitoring.
Patients with a history of severe allergic reactions to nucleoside analogs.
Known bleeding disorders or active hemorrhage without control measures.
Prior severe toxicity from gemcitabine incompatible with further treatment.
Active respiratory insufficiency or pulmonary fibrosis that may be exacerbated.
Concurrent use of medications with severe pharmacokinetic interactions increasing toxicity.
Known sensitivity to diluents or additives used in the formulation.
Severe electrolyte imbalances not corrected before initiating therapy.
Poor performance status patients unlikely to tolerate cytotoxic chemotherapy.

Drug Interactions

Increased myelosuppression when combined with other myelosuppressive agents such as cisplatin, carboplatin, or paclitaxel.
Additive pulmonary toxicity when used concomitantly with radiation therapy or other pneumotoxic drugs.
Potential pharmacokinetic interactions with drugs affecting renal function altering gemcitabine metabolite clearance.
Avoid concurrent use of live vaccines which might increase risk of viral infections.
Possible antagonism with agents interfering with phosphorylation enzymes required for activation.
Enhanced hepatotoxicity when used with other hepatotoxic drugs necessitating liver function monitoring.
Interactions with drugs metabolized by cytidine deaminase pathway may alter gemcitabine metabolism.
Combination with immunosuppressive agents may potentiate immunosuppressive effects and infection risk.
Co-administration with anticoagulants requires monitoring due to bleeding risk potentiation.
Synergistic efficacy observed with platinum compounds but with increased hematologic toxicity.
Drugs that affect nucleotide pools may influence gemcitabine's cytotoxic efficacy.
Use caution when combined with drugs causing renal impairment as it affects elimination of metabolites.
Nonsteroidal anti-inflammatory drugs may exacerbate hematologic toxicity when used concurrently.
Concurrent administration with other chemotherapy agents requires dose and schedule coordination to minimize toxicity.
Herbal supplements that induce hepatic enzymes may alter gemcitabine plasma concentrations.

Preparations Of The Drug

Gemzar sterile lyophilized powder for injection available in 200 mg, 1000 mg, and 1500 mg single-dose vials.
Supplied as a pale yellow to slightly yellow lyophilized cake or powder for reconstitution.
Requires reconstitution with sterile water for injection before dilution in appropriate intravenous fluid.
Prepared solutions are stable for limited time; administration should follow institutional guidelines to maintain sterility and potency.
Administered via intravenous infusion; infusion time typically 30 minutes but may vary based on protocol.
Packaging includes protective materials to ensure product stability and prevent contamination.
Supplied without preservatives; must be used immediately after reconstitution to minimize microbial growth risk.
Manufactured under sterile conditions complying with FDA and international pharmacopeia standards.
Available under brand name Gemzar, as well as generic versions in some countries.
Preparation and handling require appropriate protective equipment due to cytotoxicity.
Storage conditions include refrigeration between 2°C and 8°C prior to reconstitution.
Discard unused portions following aseptic technique to avoid exposure and contamination.
Instructions include warnings about accidental exposure and recommended decontamination procedures.
Packaging and labeling include detailed dosing information, contraindications, and administration guidelines.
Compounding in clinical settings should adhere to established protocols for hazardous drug handling.